You are here

  • Home
  • Archive
  • Volume 17, Issue 5
  • For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding

https://doi.org/10.1136/ebmed-2011-100343

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests JPP received grants for clinical research from Johnson & Johnson and Bayer Healthcare and was an investigator in the ROCKET AF trial. He serves as a consultant to Janssen Pharmaceuticals, Forrest Laboratories and Sanofi Aventis. MS has no conflicting interests.